Healthcare · Biotechnology
Price
$3.03
Market Cap
$126.2M
Employees
316
Beta
1.54
Avg Volume
846,562
CEO
Garo H. Armen
Business Description
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
1.78
Stock Price: $3.03
EPS (Diluted): 0.00
EPS (Diluted): 0.00
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.34
Stock Price: $3.03
Total Equity: -$271.11M
Shares: 29,734,000
Total Equity: -$271.11M
Shares: 29,734,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
3.11
Market Cap: $126.18M
Total Debt: $324.77M
Cash: $3.00M
EBITDA: $62.19M
Total Debt: $324.77M
Cash: $3.00M
EBITDA: $62.19M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$425.3M
Market Cap: $126.18M
Total Debt: $324.77M
Cash: $3.00M
Total Debt: $324.77M
Cash: $3.00M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
29.6%
Gross Profit: $33.84M
Revenue: $114.20M
Revenue: $114.20M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-18.0%
Operating Income: -$20.56M
Revenue: $114.20M
Revenue: $114.20M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.1%
Net Income: $115,000
Revenue: $114.20M
Revenue: $114.20M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-23.1%
Net Income: $115,000
Total Equity: -$271.11M
Total Equity: -$271.11M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
10.5%
Operating Income: -$20.56M
Tax Rate: 0.0%
Equity: -$271.11M
Total Debt: $324.77M
Cash: $3.00M
Tax Rate: 0.0%
Equity: -$271.11M
Total Debt: $324.77M
Cash: $3.00M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.41
Current Assets: $133.44M
Current Liabilities: $323.49M
Current Liabilities: $323.49M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-1.20
Short-Term Debt: $155.11M
Long-Term Debt: $169.66M
Total Debt: $324.77M
Total Equity: -$271.11M
Long-Term Debt: $169.66M
Total Debt: $324.77M
Total Equity: -$271.11M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$3.84
Revenue: $114.20M
Shares: 29,734,000
Shares: 29,734,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-9.12
Total Equity: -$271.11M
Shares: 29,734,000
Shares: 29,734,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-5.34
Operating CF: -$158.32M
CapEx: -$576,000
Shares: 29,734,000
CapEx: -$576,000
Shares: 29,734,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.03
Stock Price: $3.03
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $115,000
Net Income: $115,000
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AGEN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 4:04am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Cost of Revenue | $182.1M | $197.3M | $237.7M | $156.0M | $80.4M |
| Gross Profit | $113.6M | -$99.2M | -$81.4M | -$52.6M | $33.8M |
| Operating Expenses | $87.8M | $80.2M | $78.2M | $67.9M | $54.4M |
| Operating Income | $25.7M | -$179.4M | -$159.5M | -$120.5M | -$20.6M |
| Net Income | -$23.9M | -$220.1M | -$245.8M | -$227.2M | $115,000 |
| EBITDA | $43.8M | -$161.8M | -$145.9M | -$101.3M | $62.2M |
| EPS | $-2.11 | $-15.64 | $-13.75 | $-10.59 | $0.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 4:04am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $291.9M | $178.7M | $76.1M | $40.4M | $3.0M |
| Total Current Assets | $332.0M | $213.1M | $112.4M | $45.6M | $133.4M |
| Total Assets | $466.0M | $413.6M | $313.9M | $226.3M | $226.8M |
| Current Liabilities | $156.9M | $189.0M | $255.9M | $221.4M | $323.5M |
| Long-Term Debt | $12.8M | $12.6M | $12.8M | $30.5M | $169.7M |
| Total Liabilities | $418.0M | $468.5M | $462.3M | $532.7M | $504.7M |
| Total Equity | $34.4M | -$61.3M | -$160.3M | -$326.4M | -$271.1M |
| Retained Earnings | -$1.5B | -$1.7B | -$2.0B | -$2.2B | -$2.2B |
Cash Flow (Annual)
Last updated: Jun 23, 2026 4:04am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $10.1M | -$175.4M | -$224.2M | -$158.3M | -$158.3M |
| Capital Expenditure | -$33.8M | -$53.1M | -$10.0M | $-576,000 | $-576,000 |
| Free Cash Flow | -$23.7M | -$228.4M | -$234.2M | -$158.9M | -$158.9M |
| Acquisitions (net) | $0 | -$2.9M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.7M | -$3.8M | -$5.2M | $0 | $-87,000 |
| Net Change in Cash | $192.1M | -$113.3M | -$101.6M | -$35.7M | -$35.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 7:45pm (13h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$137.9M $137.4M – $138.4M
|
$128.0M $123.0M – $133.0M
|
$137.8M $124.9M – $150.7M
|
$175.8M $159.4M – $192.2M
|
| EBITDA |
-$61.2M -$61.4M – -$61.0M
|
-$56.8M -$59.1M – -$54.6M
|
-$61.2M -$66.9M – -$55.5M
|
-$78.1M -$85.4M – -$70.8M
|
| Net Income |
-$5.4M -$6.0M – -$4.7M
|
-$16.7M -$18.7M – -$14.6M
|
-$10.1M -$11.3M – -$8.9M
|
$2.7M $2.4M – $3.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 4:04am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -66.8% | +59.5% | -33.8% | +10.4% |
| Gross Profit Growth | -187.4% | +18.0% | +35.4% | +164.4% |
| Operating Income Growth | -796.9% | +11.1% | +24.5% | +82.9% |
| Net Income Growth | -819.8% | -11.7% | +7.5% | +100.1% |
| EBITDA Growth | -469.7% | +9.8% | +30.6% | +161.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:50am (3h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-12 | ARMEN GARO H | A-Award | 4,925.00 | $3.30 | $16,253 |
| 2026-05-29 | ARMEN GARO H | A-Award | 4,644.00 | $3.50 | $16,254 |
| 2026-05-15 | ARMEN GARO H | A-Award | 4,540.00 | $3.58 | $16,253 |
| 2026-05-01 | ARMEN GARO H | A-Award | 4,233.00 | $3.84 | $16,255 |
| 2026-04-24 | Hirsch Susan B | A-Award | 105,000.00 | $3.90 | $409,500 |
| 2026-04-24 | Buell Jennifer | A-Award | 300,000.00 | $3.90 | $1.2M |
| 2026-04-24 | Buell Jennifer | A-Award | 5,000.00 | $3.90 | $19,500 |
| 2026-04-24 | O'Day Steven J | A-Award | 95,333.00 | $3.90 | $371,799 |
| 2026-04-24 | O'Day Steven J | A-Award | 70,000.00 | $3.90 | $273,000 |
| 2026-04-24 | HARRISON THOMAS L | A-Award | 122,500.00 | $3.90 | $477,750 |
| 2026-04-24 | Wright Timothy | A-Award | 105,000.00 | $3.90 | $409,500 |
| 2026-04-24 | Charette Austin | A-Award | 17,619.00 | $3.90 | $68,714 |
| 2026-04-24 | Charette Austin | A-Award | 5,000.00 | $3.90 | $19,500 |
| 2026-04-24 | ARMEN GARO H | A-Award | 1,000,000.00 | $3.90 | $3.9M |
| 2026-04-24 | ARMEN GARO H | A-Award | 137,550.00 | $3.90 | $536,445 |
| 2026-04-24 | ARMEN GARO H | A-Award | 27,750.00 | $3.90 | $108,225 |
| 2026-04-24 | Corvese Brian | A-Award | 210,000.00 | $3.90 | $819,000 |
| 2026-04-17 | ARMEN GARO H | A-Award | 3,403.00 | $4.79 | $16,300 |
| 2026-04-01 | HARRISON THOMAS L | A-Award | 9,228.00 | $3.32 | $30,628 |
| 2026-04-03 | ARMEN GARO H | A-Award | 4,629.00 | $3.33 | $15,415 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AGEN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AGEN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30